PMID- 11579314
OWN - NLM
STAT- MEDLINE
DCOM- 20011018
LR  - 20190713
IS  - 0041-1337 (Print)
IS  - 0041-1337 (Linking)
VI  - 72
IP  - 6
DP  - 2001 Sep 27
TI  - New method for thyroid transplantation across major histocompatibility complex 
      barriers using allogeneic bone marrow transplantation.
PG  - 1144-9
AB  - BACKGROUND: It has been shown that allogeneic bone marrow transplantation (BMT) 
      after lethal irradiation elicits donor-specific tolerance for organ or tissue 
      transplantation across major histocompatibility complex (MHC) barriers. Recently, 
      we have demonstrated that the portal venous (p.v.) administration of donor bone 
      marrow cells (BMCs) elicits donor-specific tolerance across MHC barriers by only 
      two administrations of an immunosuppressant (CsA or FK-506). In our study, using 
      the central and intrahepatic tolerance-inducing system, we have established a new 
      method for thyroid transplantation with BMT that would be more applicable to 
      humans. METHODS: In addition to sublethal (6-5 Gy) irradiation, recipient B6 
      (H-2b) mice received injections i.p. with the myeloablative drug busulfan (BU) on 
      day -2 to provide a sufficient "space" for the donor hematopoietic cells to 
      expand in the recipients. To induce the intrahepatic tolerance, donor BALB/c 
      (H-2d) BMCs were treated with neuraminidase (Neu), which enhances the trapping of 
      i.v. injected BMCs in the liver. After the injection of Neu-treated BMCs, the 
      thyroid organs from the BALB/c mice were engrafted under the renal capsules. 
      RESULTS: A 90% graft survival rate was obtained over 100 days by a combination of 
      BU administration, 6 Gy irradiation, and i.v. injection of Neu-treated BMCs [BU+6 
      Gy+(Neu) i.v.], and a 70% graft survival rate was obtained by [BU+5 Gy+(Neu) 
      i.v.]. However, the graft survival rate significantly decreased when either the 
      BU or Neu treatment was omitted. T cells collected from the tolerant recipients 
      suppressed the proliferative responses to donor alloantigens. CONCLUSIONS: Using 
      both BU and Neu treatments, we have succeeded in inducing long-term tolerance and 
      preventing the rejection of thyroid allografts by the single-day protocol.
FAU - Lee, S
AU  - Lee S
AD  - First Department of Pathology, Kansai Medical University, 10-15 Fumizono-cho, 
      Moriguchi City, Osaka 570-8506, Japan.
FAU - Sugiura, K
AU  - Sugiura K
FAU - Nagahama, T
AU  - Nagahama T
FAU - Iwai, H
AU  - Iwai H
FAU - Yasumizu, R
AU  - Yasumizu R
FAU - Yamashita, T
AU  - Yamashita T
FAU - Ikehara, S
AU  - Ikehara S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
RN  - 0 (Myeloablative Agonists)
RN  - EC 3.2.1.18 (Neuraminidase)
RN  - G1LN9045DK (Busulfan)
SB  - IM
MH  - Animals
MH  - Bone Marrow Cells/drug effects
MH  - *Bone Marrow Transplantation
MH  - Busulfan/therapeutic use
MH  - Graft Survival
MH  - Lymphocyte Culture Test, Mixed
MH  - *Major Histocompatibility Complex
MH  - Mice
MH  - Mice, Inbred Strains
MH  - Myeloablative Agonists/therapeutic use
MH  - Neuraminidase/therapeutic use
MH  - Organ Transplantation/*methods
MH  - Spleen/pathology
MH  - Thyroid Gland/*transplantation
MH  - Transplantation Chimera
MH  - *Transplantation Immunology
MH  - Transplantation, Homologous
EDAT- 2001/10/02 10:00
MHDA- 2001/10/19 10:01
CRDT- 2001/10/02 10:00
PHST- 2001/10/02 10:00 [pubmed]
PHST- 2001/10/19 10:01 [medline]
PHST- 2001/10/02 10:00 [entrez]
AID - 10.1097/00007890-200109270-00027 [doi]
PST - ppublish
SO  - Transplantation. 2001 Sep 27;72(6):1144-9. doi: 10.1097/00007890-200109270-00027.